Connect to other sites within the UBM Medica Network
Socioeconomic Factors, Not Race, Influenced Myeloma Survival in Younger Patients
Socioeconomic factors affected the care and survival of younger patients with multiple myeloma, but race/ethnicity itself did not influence survival.
CLL Patients Responded to Influenza Vaccine
Patients with chronic lymphocytic leukemia (CLL) taking ibrutinib showed an antibody response to the influenza vaccine, according to a data from a small study.
Mogamulizumab for Adult T-Cell Leukemia/Lymphoma Associated With Increased Mortality
Patients with adult T-cell leukemia/lymphoma treated with mogamulizumab prior to undergoing allo-HSCT were at significantly greater risk for graft-vs-host disease–related mortality.
Molecular Monitoring of Cell-Free Circulating Tumor DNA in Non-Hodgkin Lymphoma
In this review, we discuss the potential applications of monitoring ctDNA in patients with diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma.
Precision Monitoring by Next-Generation Sequencing in Lymphoma: Circulating Tumor DNA as a New Biomarker
It is clear that as our understanding of both aggressive and indolent lymphomas improves, the goals of treatment change and the bar for success is set higher.
An 84-Year-Old Woman With an Indolent B-Cell Lymphoma
An 84-year-old woman with a history of Graves disease, hyperlipidemia, and hypertension presented to her physician with progressive fatigue and palpable bilateral axillary lymphadenopathy.
Nilotinib, Dasatinib Offer Similar Outcomes in CML Patients
A propensity score–matched comparison of two phase II trials found that dasatinib and nilotinib offer similar responses and outcomes as first-line therapy for patients with chronic-phase CML.
Upfront ASCT Still Best Option in Newly Diagnosed Multiple Myeloma
In this video we discuss the results of a phase III trial that studied upfront high-dose chemotherapy plus autologous stem cell transplantation (ASCT) compared to chemotherapy alone and bortezomib in newly diagnosed multiple myeloma.
Ibrutinib Improves on Standard of Care in CLL/SLL
A trial found that ibrutinib in combination with bendamustine and rituximab is superior to standard of care in patients with previously treated CLL/SLL.
T-Cell Therapy Produced Prolonged Remission in Relapsed Pediatric ALL
In this video from the 2014 ASH Meeting, Dr. Grupp discusses data from a trial using CAR T-cell therapy in children and young adults with relapsed, treatment-resistant ALL.
Sorafenib Demonstrates Activity in AML
In this video from the 2014 ASH Annual Meeting, Dr. Röllig discusses the results of the SORAML trial that tested sorafenib in patients with acute myeloid leukemia.
By clicking Accept, you agree to become a member of the UBM Medica Community.